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Abstract
 
The complement anaphylatoxin C5a and its seven-transmembrane segment (7TMS) receptor
play an important role in host defense and in a number of inflammation-associated pathologies.
 
The NH
 
2
 
-terminal domain of the C5a receptor (C5aR/CD88) contributes substantially to its
ability to bind C5a. Here we show that the tyrosines at positions 11 and 14 of the C5aR are
posttranslationally modified by the addition of sulfate groups. The sulfate moieties of each of
these tyrosines are critical to the ability of the C5aR to bind C5a and to mobilize calcium. A
C5aR variant lacking these sulfate moieties efficiently mobilized calcium in response to a small
peptide agonist, but not to C5a, consistent with a two-site model of ligand association in which
the tyrosine-sulfated region of the C5aR mediates the initial docking interaction. A peptide
based on the NH
 
2 
 
terminus of the C5aR and sulfated at these two tyrosines, but not its unsul-
fated analogue or a doubly sulfated control peptide, partially inhibited C5a association with its
receptor. These observations clarify structural and mutagenic studies of the C5a/C5aR associa-
tion and suggest that related 7TMS receptors are also modified by functionally important sul-
fate groups on their NH
 
2
 
-terminal tyrosines.
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Introduction
 
The anaphylatoxin C5a is a proteolytic fragment of the fifth
component of complement generated during activation.
C5a and its G protein–coupled, seven-transmembrane seg-
ment (7TMS)
 
1
 
 receptor, C5aR, play central roles in a
number of protective and pathological inflammatory pro-
cesses including rheumatoid arthritis, psoriasis, septic shock,
myocardial ischemia injury, acute respiratory distress syn-
drome, and multiple system organ failure (for reviews, see
references 1 and 2).
 
Like other chemotactic 7TMS receptors of the immune
system, including most or all chemokine receptors, the
 
NH
 
2
 
-terminal extracellular domain of the C5aR contains
several tyrosines adjacent to a number of acidic amino acids
(3). A number of studies with chimeras and point mutations
have shown that the NH
 
2
 
-terminal domain proximal to
these tyrosines plays an important role in the ability of the
C5aR to associate with C5a (4–11). Somewhat inconsis-
tently with these studies, a recent nuclear magnetic reson-
ance (NMR) study of the interaction between C5a and an
unsulfated peptide based on the C5aR NH
 
2 
 
terminus (1–30)
suggested that the majority of binding energy derived from
residues 21–30 of the C5aR NH
 
2 
 
terminus, distal to the
NH
 
2
 
-terminal tyrosines at positions 6, 11, and 14 (12).
 
We have shown previously that a similar acidic and ty-
rosine-rich motif of the chemokine receptor CCR5 is post-
translationally modified by sulfation of most or all of its four
 
NH
 
2
 
-terminal tyrosines, and that tyrosine sulfation contrib-
utes to the ability of CCR5 to bind both its natural chemo-
kine ligands and the HIV-1 envelope glycoprotein (3). We
have also shown that a tyrosine-sulfated peptide based on the
first 22 amino acids of CCR5 blocks HIV-1 entry into
CCR5-expressing target cells, and partially inhibits the asso-
ciation of CCR5 with its natural chemokine ligands (13).
 
Address correspondence to H. Choe, Perlmutter Laboratory, Children’s
Hospital, Boston, MA 02115. Phone: 617-355-7586; Fax: 617-632-3113;
E-mail: hchoe@mbcrr.harvard.edu
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Abbreviations used in this paper:
 
 CCR5, CC chemokine receptor 5;
Cha, cyclohexylalanine; NMR, nuclear magnetic resonance; 7TMS,
seven-transmembrane segment. 
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Tyrosine Sulfation of the C5a Receptor
 
Here we demonstrate that two tyrosines of the C5aR
NH
 
2
 
 terminus are sulfated and show that this posttransla-
tional modification is critical for efficient association of in-
tact C5a with the C5aR, but not for the receptor to signal
through a small synthetic peptide agonist. We also demon-
strate that a tyrosine-sulfated peptide corresponding to resi-
dues 7 through 28 of the NH
 
2 
 
terminus of C5aR, but not
its unsulfated equivalent or a doubly tyrosine-sulfated pep-
tide derived from CCR5, partially blocks the association of
C5a with its receptor. These data underscore the impor-
tance of tyrosine sulfation in many chemotactic and inflam-
matory processes, and provide new structural insight into
the association of C5a with its receptor.
 
Materials and Methods
 
Cells, Plasmids, Antibodies, and Peptides.
 
HEK293T cells
were obtained from the American Tissue Type Collection
(CRL11554). An expression plasmid encoding the human C5aR
with the addition of a nine amino acid extension at its COOH
terminus (corresponding to the nine COOH-terminal amino ac-
ids of bovine rhodopsin, TETSQVAPA) was generated by PCR
amplification of a plasmid encoding human C5aR (14) into a
pcDNA3.1 (Invitrogen) expression vector containing a region
encoding the bovine rhodopsin COOH terminus (3), facilitating
recognition by the antibody 1D4 (provided by the National Cell
Culture Center, Minneapolis, MN). Plasmids encoding C5aR
variants YFF, YFY, YYF, and L2-FF in which one or more ty-
rosines were altered to phenylalanine were generated by the
QuikChange method (Stratagene), and sequenced in their coding
regions. Anti-C5aR antibody S5/1 was provided by Dr. O. Gotze
(Georg-August-University, Gottingen, Germany) (15). Tyrosine-
sulfated peptides and their unsulfated analogues (TTPDY
 
*
 
GHY
 
*
 
DDKDTLDLNTPVDK, asterisks indicate sulfated tyrosines,
identified here as “S-peptide”, its unsulfated equivalent identified
as “C-peptide”, or a sulfated CCR5-derived peptide, MDYQV-
SSPIY
 
*
 
DINY
 
*
 
YTSEPSQK, “R5-S-peptide”) were synthesized
to 95% purity by American Peptide Company. Small peptide
C5aR agonist (F-K-A-dCha-Cha-dR, where Cha indicates cy-
clohexylalanine; reference 6) was synthesized to 95% purity by
New England Peptide.
 
Labeling and Immunoprecipitation of C5aR and C5aR Variants.
 
HEK293T cells were transfected with plasmid encoding wild-
type C5aR or C5aR variants by the calcium phosphate method.
Approximately 36 h after transfection, cells were washed twice in
PBS, divided, and labeled with [
 
35
 
S]cysteine and [
 
35
 
S]methionine
or with [
 
35
 
S]sulfate overnight. In some experiments, 5 
 
m
 
g/ml tu-
nicamycin (Sigma-Aldrich) was added to the cell culture media 5 h
before radiolabeling, and during the labeling to inhibit N-glyco-
sylation of the receptor. Labeled cells were lysed in 1% Cymal-6
(Anatrace) in PBS containing a protease inhibitor cocktail
(Sigma-Aldrich) and 0.2 mM PMSF. Labeled receptor was im-
munoprecipitated in the presence of 1% SDS with 1D4 antibody
covalently linked to Sepharose beads (Amersham Pharmacia Bio-
tech). Immunoprecipitates were washed in PBS containing 1%
Cymal-6 and 1% SDS, incubated at 55
 
8
 
C for 10 min in reducing
sample buffer, and analyzed by 10% SDS-PAGE.
 
Binding of C5a to Cells Expressing C5aR Variants or in the Pres-
ence of Sulfated and Unsulfated Peptides.
 
Binding experiments
were performed with HEK293T cells transfected as described
above. 2 
 
3 
 
10
 
5
 
 cells were incubated with 0.2 nM [
 
125
 
I]C5a (Du-
 
pont/NEN Life Science Products) and 0 to 300 nM unlabeled
C5a (Sigma-Aldrich) for 30 min at 37
 
8
 
C in binding buffer (50
mM Hepes, pH 7.4, 1 mM CaCl
 
2
 
, 1 mM MgCl
 
2
 
, 0.2% BSA, and
0.02% NaN
 
3
 
). In parallel, FACS
 
®
 
 analysis was performed on 5 
 
3
 
10
 
5 
 
of the same cells stained with 0.5 
 
m
 
g/ml of the anti-C5aR an-
tibody S1/5 (15) and then with FITC-conjugated goat anti–
mouse IgG (Sigma-Aldrich).
Inhibition of C5a binding by a sulfated C5aR-derived peptide
(S-peptide, corresponding to residues 7–29 of the C5aR), its un-
sulfated equivalent (C-peptide), or sulfated peptide corresponding
to the 22 NH
 
2
 
-terminal residues of CCR5 (R5-S-peptide) was
determined by incubating cells with 0.2 nM [
 
125
 
I]C5a in the pres-
ence or absence of peptides at the concentrations indicated.
 
Calcium Mobilization Mediated by the C5aR and a C5aR Vari-
ant.
 
Approximately 3 
 
3
 
 10
 
6
 
 HEK293T cells were transfected
with 15 
 
m
 
g of plasmid encoding wild-type C5aR or the YFF
variant together with 15 
 
m
 
g of plasmid encoding the G protein
component G
 
a
 
16
 
, which has been shown necessary for C5a-
mediated signal transduction (16). Cells were harvested at 48 h,
washed, and incubated with the indicator dye Fura-2/AM (Mo-
lecular Probes) for 1 h at 37
 
8
 
C in 20 mM Hepes, pH 7.4, 1 mM
CaCl
 
2
 
, 1 mM MgCl
 
2
 
, 125 mM NaCl, 5 mM KCl, 0.5 mM glu-
cose, and 0.2% BSA (17). Cells were washed twice and resus-
pended in the same buffer at 2 
 
3 
 
10
 
6
 
/ml. Changes in intracellular
calcium concentrations in response to C5a or a small synthetic
peptide C5aR agonist (F-K-A-dCha-Cha-dR; reference 6) were
determined by monitoring the emission at 510 nm of the excita-
tion at 340 and 380 nm as a function of time. Responses were
quantified as the peak of the ratio of 340/380 nm wavelengths.
 
Results
 
Tyrosines at Positions 11 and 14 of the C5aR Are Sul-
fated.
 
Human C5aR has five tyrosines in its extracellular
domains: at positions 6, 11, and 14 at its NH
 
2 
 
terminus (see
Fig. 4 B) and at positions 181 and 192 in its second extra-
cellular loop (14). Among these, all but tyrosine 6 are im-
mediately adjacent to one or more acidic residues, a feature
suggestive of tyrosine sulfation (18–20). Tyrosine 6 is also
adjacent to the NH
 
2
 
-terminal glycosylation site of the
C5aR at asparagine 5 and as such is less likely to be sulfated
than the remaining tyrosines (18). We also speculated that
the relatively accessible NH
 
2
 
-terminal domain of the re-
ceptor would be more likely to be sulfated than the second
extracellular loop of the C5aR, consistent with our obser-
vations in the case of the chemokine receptor CCR5 (3).
We therefore focused our initial investigations on the
NH
 
2
 
-terminal tyrosines 11 and 14.
We first examined whether the C5aR could efficiently
incorporate [
 
35
 
S]sulfate. An expression plasmid encoding
the human C5aR with a nine amino acid COOH-terminal
tag derived from bovine rhodopsin was transfected into
HEK293T cells. Cells were divided, radiolabeled with ei-
ther [
 
35
 
S]cysteine and [
 
35
 
S]methionine or [
 
35
 
S]sulfate, lysed,
and lysates were immunoprecipitated and analyzed by
SDS-PAGE. Fig. 1 A demonstrates that when tagged wild-
type C5aR was expressed in 293T cells and labeled with
[
 
35
 
S]cysteine and [
 
35
 
S]methionine, four discrete bands could
be observed (Fig. 1 A, lane 2). The top two bands appear to
represent mature glycosylated and unglycosylated forms of 
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the receptor (compare lane 2 of Figs. 1, A and B), whereas
the bottom two bands migrate faster than unmodified full-
length C5aR and may represent proteolytic products of the
receptor, as suggested by pulse chase analysis (data not
shown). Lane 6 of Fig. 1 A demonstrates that two larger
forms of wild-type C5aR specifically incorporated [
 
35
 
S]sul-
fate, implying that these forms transit through the trans-
Golgi network where sulfation occurs (18, 21, 22), whereas
the smaller bands observed in lysates labeled with [
 
35
 
S]cys-
teine and [
 
35
 
S]methionine did not incorporate [
 
35
 
S]sulfate
(compare lanes 2 and 6 of Fig. 1 A). We conclude that the
full-length C5aR is modified by the addition of sulfate and
that at least some of these sulfate moieties are independent
of glycosylation present on the molecule.
Fig. 1 A also shows that a variant of the C5aR in which
NH
 
2
 
-terminal tyrosines 11 and 14 are modified to phenyl-
alanine (denoted YFF to indicate amino acid present at po-
sitions 6, 11, and 14, respectively, of the variant receptor)
only weakly incorporated radiolabeled sulfate in its glyco-
sylated form, and could not incorporate sulfate in its mature
unglycosylated form (Fig. 1 A, lanes 3 and 7). Another re-
ceptor variant, YYF, in which tyrosine 14 alone was al-
tered to phenylalanine, could incorporate radiolabeled sul-
fate in both its glycosylated and unglycosylated forms, but
substantially less efficiently than wild-type C5aR (Fig. 1 A,
lane 8). A receptor variant (YFY) in which tyrosine 10
alone was altered to phenylalanine also incorporated sub-
stantially lower levels of radiolabeled sulfate than wild-type
C5aR receptor (data not shown). Taken together, these
data show that tyrosines at positions 11 and 14 are modified
by sulfate.
We further investigated the source of the residual sulfa-
tion observed with the YFF variant. Constructs expressing
wild-type C5aR or the YFF variants were transfected into
HEK293T cells and treated with the N-glycosylation in-
hibitor tunicamycin. Cells were divided, radiolabeled with
[
 
35
 
S]cysteine and [
 
35
 
S]methionine or [
 
35
 
S]sulfate in the pres-
ence of tunicamycin, and analyzed as above. Fig. 1 B shows
that the majority of immunoprecipitated wild-type and
YFF C5aR was found in an unglycosylated form (Fig. 1 B,
lanes 2 and 3). Wild-type C5aR could efficiently incorpo-
rate [
 
35
 
S]sulfate (Fig. 1 B, lane 5), but the YFF C5aR vari-
ant could not incorporate detectable [
 
35
 
S]sulfate (Fig. 1 B,
lane 6), even after extended exposure (data not shown).
We conclude that tyrosines 11 and 14 are the only ty-
rosines present on the C5aR posttranslationally modified
by sulfate and that the N-linked glycosylation of the C5aR
may also incorporate some radiolabeled sulfate.
 
Sulfate Moieties at Tyrosines 11 and 14 of C5aR Contribute
to C5a Association.
 
We next investigated the ability of
C5a to bind wild-type C5aR and C5aR variants in which
one or both of the sulfated tyrosines had been altered to
Figure 1. Wild-type C5aR, but not a C5aR variant lacking tyrosines
11 and 14, efficiently incorporates radiolabeled sulfate. (A) HEK293T cells
were transfected with vector alone or plasmids encoding wild-type (wt)
C5aR (YYY, denoting NH2-terminal tyrosines at positions 6, 10, and 14),
or variant receptors in which tyrosines 11 and 14 (YFF) or tyrosine 14
alone (YYF) had been altered to phenylalanine. Cells were split, radiola-
beled with [35S]cysteine and [35S]methionine or [35S]sulfate, as indicated,
and lysed. Cell lysates were incubated with the antibody 1D4 that recog-
nizes a tag COOH-terminal to C5aR and C5aR variants, and immuno-
precipitates were analyzed by SDS-PAGE. (B) Experiment similar to panel
A except that cells were treated with the N-glycosylation inhibitor tunica-
mycin before and during radiolabeling.
Figure 2. Sulfate moieties at C5aR tyrosines 11 and 14 contribute to
C5a association. (A) HEK293T cells were transfected with plasmids en-
coding wild-type (wt) C5aR (YYY; h), a C5aR variant in which ty-
rosines 11 and 14 were altered to phenylalanine (YFF; s), or a construct
in which two tyrosines in the C5aR second loop were altered to phenyl-
alanine (L2-FF; ,). Cells were incubated with the 0.2 nM [125I]C5a and
the indicated amounts of unradiolabeled C5a competitor. Cells were
washed, and bound [125I]C5a was quantitated by scintillation counting.
FACS® measurements were performed in parallel on the same cells with
the anti-C5aR antibody S5/1 (reference 15). Mean fluorescence for cells
expressing wild-type C5a was measured at 374; for L2-FF, 352; and for
YFF, 532. Mean fluorescence for mock transfected cells was 7.3. (B) An
experiment similar to that in panel A using HEK293T cells expressing the
wild-type C5aR (YYY; h), or the variants YYF (e), YFY (n), or YFF
(s). In this experiment, mean fluorescence values of cells expressing
wild-type C5ar (YYY) was 383; YYF, 400; YFY, 383; YFF, 430; and
mock-transfected, 6.6. Experiments are representative of two (A) or three
(B) experiments performed with similar results. 
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phenylalanine. HEK293T cells were transfected with wild-
type C5aR, the YFF variant, or a C5aR variant in which
the two tyrosines of the second extracellular loop of C5aR
(tyrosines 181 and 192) had been altered to phenylalanine
(denoted L2-FF). The ability of cells transfected with each
of these constructs to bind [
 
125
 
I]C5a was assayed in the
presence of increasing concentration of unlabeled C5a
competitor. In parallel, an aliquot of these same cells was
assayed by FACS
 
®
 
 analysis of their surface expression of the
receptor using the S5/1 anti-C5a antibody (15). Fig. 2 A
demonstrates that cells transfected with the wild-type
C5aR or the L2-FF variant expressed comparable levels of
receptor (Fig. 2 legend) and bound [
 
125
 
I]C5a with similar
affinities (measured dissociation constants of 2.7 
 
6 
 
0.7 nM
and 2.6 
 
6 
 
0.8 nM for wild-type C5aR and the L2-FF vari-
ant, respectively). In contrast, the YFF C5aR variant ex-
pressed comparably or more efficiently than wild-type
C5aR, but could not detectably associate with [
 
125
 
I]C5a
(Fig. 2 A and Fig. 2 legend).
We also examined the specific contribution of each of
the two tyrosine sulfate moieties of the C5aR to C5a bind-
ing by assaying receptor variants (YFY and YYF) in which
tyrosines 11 and 14 had been altered individually to phenyl-
alanine. Fig. 2 B shows that cells transfected with either
the YFY variant or the YYF variant bound [
 
125
 
I]C5a sub-
stantially less efficiently than wild-type C5aR, but more ef-
ficiently than the YFF variant, despite the fact that all re-
ceptors expressed at comparable levels (Fig. 2 legend). The
C5aR variant lacking a sulfate moiety at position 11 (YFY)
bound [
 
125
 
I]C5a less efficiently than the variant lacking a
sulfate at position 14 (YYF), suggesting a greater role for
 
the sulfate moiety at position 11. These data show that
both tyrosine sulfate moieties of the C5aR NH
 
2 
 
terminus
contribute to the formation of a C5a binding site.
 
The Efficiency of Calcium Mobilization by the C5aR Is Not
Dependent on Sulfated Tyrosines.
 
Like many 7TMS super-
family receptors with protein ligands, the C5aR binds its
ligand at two conformationally distinct receptor sites (9, 10,
23, 24). The first or docking site, which includes the NH
 
2
 
-
terminus of the receptor, is known to contribute substan-
tially to the binding energy of the receptor–ligand associa-
tion, whereas the second or activation site is thought to
include a pocket formed by the transmembrane helices. This
second site is likely the sole site involved in the association
of 7TMS receptors with small nonprotein ligands such as
dopamine or acetylcholine, and is sufficient for receptor
signaling with a small peptide in the case of the C5aR (6,
23). We therefore sought to determine if sulfated tyrosines
of the NH
 
2
 
 terminus of C5aR contributed to the forma-
tion of the second receptor site as well as the first.
Dose–response curves for changes in intracellular cal-
cium induced in cells expressing wild-type C5aR or the
YFF variant incubated with either C5a or a small peptide
agonist (F-K-A-dCha-Cha-dR) are shown in Fig. 3. This
latter agonist has been previously demonstrated to signal
through the C5aR independently of the receptor NH
 
2 
 
ter-
minus (6). Expectedly, as shown in Fig. 3 A, a 200- to
1,000-fold higher concentration of C5a was necessary to
induce a similar level of calcium mobilization in cells ex-
pressing the YFF variant compared with cells expressing
wild-type C5aR, reflecting the substantially reduced ability
of C5a to bind the YFF receptor observed in Fig. 2. In
Figure 3. A C5aR variant lacking ty-
rosines 11 and 14 mobilizes calcium in
response to a small peptide agonist, but
not to C5a. 293T cells were transfected
with plasmid encoding wild-type (wt)
C5aR (d) or the YFF C5aR variant (s)
and a plasmid encoding the G protein
component Ga16. Cells were then la-
beled with calcium indicator dye Fura-2,
and assayed for their ability to mobilize
calcium in response to the indicated
concentrations of C5a (A) or a small
peptide C5aR agonist (reference 6) (B).
Calcium mobilization is shown as the
difference between the flux peak and the
background levels of the ratios between
the emission observed at 510 nm after
excitation at 340 and 380 nm wave-
lengths. (C) Representative peaks of the
type used to generate the dose–response
curves in panel A observed with cells ex-
pressing wild-type C5aR or the YFF
variant, as indicated, and treated with
0.2 nM C5a. (D) Representative peaks
of the type used to generate the curves
in B, treated with 500 nM agonist pep-
tide. Triangles indicate time of introduc-
tion of C5a (C) or peptide agonist (D).
A representative experiment of two ex-
periments performed is shown in A–D.1063 Farzan et al.
contrast, the same cells expressing wild-type C5aR or the
YFF variant responded nearly equivalently to a small pep-
tide agonist that requires only the second site of association
to mobilize calcium (Fig. 3, B and D). These data demon-
strate that tyrosine sulfation contributes to the formation of
the first site of C5a association, but not significantly to the
second site or to the ability of the C5aR to signal.
A Tyrosine-sulfated Peptide Partially Blocks Association of
C5a with C5aR. Tyrosine-sulfated peptides based on the
NH2 terminus of the chemokine receptor CCR5 have
been shown to specifically block chemokine and HIV-1
gp120 association with CCR5 at high concentrations (13,
25). Fig. 4 A demonstrates that an analogous peptide, cor-
responding to residues 7 through 28 of the C5aR NH2 ter-
minus and sulfated at tyrosines 11 and 14 (identified as
“S-peptide”; Fig. 4 B), blocked approximately half of the
specific association of 0.2 nM [125I]C5a with C5aR at
200 mM concentration. The same concentration of an un-
sulfated peptide of the same sequence (“C-peptide” in Fig.
4 A), or a doubly sulfated control peptide based on the
NH2 terminus of CCR5 (“R5-S-peptide” in Fig. 4 A) had
no significant effect on the ability of [125I]C5a to bind the
C5aR. Assuming that C5a bound to peptide lacks the abil-
ity to bind C5aR, the affinity of the S-peptide for C5a can
be placed at z200 mM, a value similar to an affinity of the
chemokine macrophage inflammatory protein (MIP)-1a
for the R5-S-peptide (13). These relatively low affinities
may reflect the participation of other components of the
receptor in ligand binding, and the high entropic barriers
that a relatively disordered peptide must overcome to adopt
its binding conformation. These data suggest a direct phys-
ical interaction between C5a and the tyrosine-sulfated NH2
terminus of the C5aR, rather than an indirect role for this
region of C5aR as has been suggested (2, 12).
Discussion
We have shown here that the C5aR contains two ty-
rosine sulfate moieties located at positions 11 and 14 in the
NH2 terminus of the receptor. These sulfates appear to play
a critical role in the association of C5aR with C5a, but no
significant role in the ability of the receptor to transduce a
signal and mobilize calcium in response to a small peptide
agonist. This latter observation confirms the conforma-
tional and functional integrity of the C5aR variants used in
this study. We have also shown that at high concentration,
a tyrosine-sulfated peptide based on the NH2 terminus of
the C5aR specifically inhibits the association of the C5aR
with C5a. These observations are consistent with a physical
interaction between the tyrosine-sulfated region of C5aR
and C5a.
The presence of two sulfate moieties on the C5aR that
contribute to its association with C5a may resolve appar-
ently contradictory observations of other studies. A C5aR
variant lacking residues 1–22 bound C5a significantly less
efficiently than wild-type C5aR (4, 6, 11). Also, alteration
of aspartic acids 10, 15, and 16 of C5aR had a similarly
pronounced effect on C5a binding (4). However, Chen et
al. (12) reported that in an NMR study of C5a bound to an
unsulfated NH2-terminal C5aR peptide, only residues 21–
30 of the C5aR NH2 terminus bound C5a. Our data sug-
gest that the discrepancy between this study and the previ-
ous mutagenic studies of C5aR is a consequence of the use
of unsulfated peptide in the former NMR study. Our data
also raise the possibility that perturbation of the C5aR
NH2-terminal aspartic acids interferes with C5a binding (4)
in part by interfering with acidic motif necessary for ty-
rosine sulfation (19, 20).
Chen et al. also investigated proton resonance perturba-
tions of C5a residues in the presence of the same NH2-ter-
minal C5aR peptide (12). They observed a number of
shifts at residues in the first loop and second helix of C5a,
but did not detect resonance shifts for a set of mostly posi-
tively charged residues in the third and fourth helix of C5a
implicated by mutagenesis in binding the C5aR (9, 12, 26,
27). These C5a residues include Arg 37, Arg 40, Leu 43,
Arg 46, Lys 49, Glu 53, and Arg 62. Most of these residues
are distal from the COOH terminus of C5a which interacts
with the second or activation site of the receptor, and
which is implicated in signaling. Thus, given the charge
complementarity of these residues and the NH2 terminus of
C5aR, it is likely that some of these residues interact with
the region of the C5aR NH2 terminus that includes sul-
fated tyrosines 11 and 14. It will be interesting to deter-
mine if a sulfated peptide induces chemical shifts in C5a in
addition to those observed by Chen et al. (12).
The prevalence of and functional role for sulfated ty-
rosines at the NH2 terminus of at least two 7TMS recep-
Figure 4. A sulfated peptide derived from the C5a NH2 terminus par-
tially inhibits C5a association with the C5aR. (A) 293T cells transfected
with wild-type C5aR were incubated with 0.2 nM [125I]C5a and the in-
dicated amount of a peptide corresponding to residues 7 through 28 of
the C5aR, with sulfated tyrosines at positions 11 and 14 (S-peptide; d),
or with unmodified tyrosines at these positions (C-peptide; s), or with a
doubly sulfated peptide based on the 22 NH2-terminal residues of the
chemokine receptor CCR5 (R5-S-peptide; .). Cells were washed, and
bound [125I]C5a was measured by gamma counting. (B) The primary se-
quence of the NH2-terminal 28 residues of the C5aR with positions of
tyrosines indicated. Sulfated tyrosines 11 and 14 are indicated with aster-
isks. The sequence of the C5aR corresponding to the sulfated peptide (S-
peptide) used in panel A is underlined. A representative experiment of
two similar experiments is shown.1064 Tyrosine Sulfation of the C5a Receptor
tors, CCR5 and the C5aR, that mediate chemotaxis sug-
gest that unique properties of the sulfate moiety contribute
to the function or regulation of these receptors. For exam-
ple, the sulfate moiety is labile at acidic pH, suggesting the
possibility that internalization of the ligand-bound receptor
into a low pH compartment and consequent loss of the sul-
fate moiety facilitates the release and degradation of ligand
and recycling of the receptor, possibly after resulfation in
the trans-Golgi network (18, 20, 21). Rapid dissocation of
ligand and receptor recycling may be especially useful in
the case of chemotactic receptors that must respond quickly
to minute concentration gradients of ligand. Also of note is
that many 7TMS receptors with relatively large protein
ligands have NH2 termini that suggest the presence of sul-
fated tyrosines (3), whereas most 7TMS receptors with
small molecule ligands lack a similar tyrosine sulfation mo-
tif. Thus, in many cases sulfated tyrosines may provide the
primary binding energy for ligand association at the dock-
ing site of the receptor, positioning the ligand appropriately
for interaction with the second, activation site. The pres-
ence and functional role of sulfate moieties on the chemo-
tactic receptors CCR5 (3), CCR2 (28), and C5aR suggest
that most of the many chemotactic 7TMS receptors con-
taining acidic and tyrosine-rich regions in their extracellular
domains are indeed tyrosine sulfated, and that sulfate moi-
eties contribute to the function of these receptors as well.
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